



Consortium for Advancing Management and Prevention of Cancer in People with HIV

AMC Operations & Data Management Center (ODMC)
The Emmes Company, LLC
401 N. Washington Street, Suite 700
Rockville, MD 20850
Phone: 301-251-1161; Fax: 240-238-2842

PRESS RELEASE

The **Consortium for Advancing Management and Prevention of Cancer in People with HIV**, formerly known as the **AIDS Malignancy Consortium**, is pleased to announce its new name and logo, while retaining the original acronym “AMC”. This rebranding reflects the Consortium’s evolving mission and commitment to advancing cancer research and care for people with HIV.

This change is the result of extensive deliberation and collaboration among the Office of HIV and AIDS Malignancy (OHAM), the AMC Executive Committee, the Patient Outcomes, Survivorship, and Engagement Committee (POSEC), and our valued community members. The new name better represents the Consortium’s broadened focus—not only on the management of cancer in people with HIV but also on prevention, as demonstrated by landmark studies such as [ANCHOR \(AMC-A01\)](#) and [COVENANT \(AMC-099\)](#).

Importantly, removing the term “AIDS” from the name offers a less stigmatizing outlook for individuals with HIV who do not have AIDS, aligning with our commitment to patient-centered care and inclusivity.

The New Logo

The redesigned logo symbolizes AMC’s mission and values through its colors and imagery.

- **Ribbon:** Represents awareness, unity, and hope in the fight against HIV-associated cancers.
- **Colors:** Dark blue, Red, and Purple
 - **Differentiate** between various cancer types.
 - **Unite** patients, survivors, families, and advocates under shared symbols of awareness.
 - **Reflect** emotional themes—strength, courage, hope—that resonate with each cancer community.

Investigators are encouraged to use the new logo and updated short forms on all AMC-sponsored or supported official documents, including memos, newsletters, publications, and abstracts.

About AMC

AMC develops and conducts innovative clinical trials for the treatment and prevention of cancer, precancerous conditions, or at high risk of developing cancer. Since its inception, AMC has launched over 100 clinical trials or research studies, enrolled over 20,000 patients, generated more than 500 publications or presentations at scientific meetings, and collected over 1.3 million biospecimens.

- The **mission** of AMC is investigate through clinical trials new treatment and prevention interventions and study the pathobiology of malignancies and their precursors in people with HIV both in the USA and internationally.
- The **vision** of AMC is to reduce incidence, morbidity, and mortality of cancers occurring in individuals with HIV.

- The **core values** of AMC include objectivity, honesty, transparency, equity, accountability, and stewardship.

Major accomplishments of AMC that had a profound **impact** on clinical practice guidelines include:

- The landmark ANCHOR trial, which established for the first time that treatment of anal precancerous lesions caused by HPV infection reduces the risk of **anal cancer**.
- Confirming the safety and efficacy of **cancer immunotherapy** targeting immune checkpoints such as PD1, which is widely used to treat many different types of cancer
- Demonstration that paclitaxel is superior to other standard treatment options for advanced **Kaposi's Sarcoma** in low-income countries in sub-Saharan Africa with limited resources.
- Confirmation that infusional chemotherapy plus rituximab immunotherapy is a safe and potentially curative treatment regimen for aggressive, deadly subtypes of **non-Hodgkin's lymphoma**.

Supported by the **National Cancer Institute (NCI)**, the AMC was founded in 1995 and now includes:

- **38 sites in the U.S., Latin America, and Africa that participate in AMC-coordinated trials**
- **4 Scientific Working Groups** that develop AMC-trials
- **4 Committees** that support the activities of AMC
- **3 Cores** providing **Administrative, Statistical, and Operational & Data Management** support. Our goal is to find better ways to treat and prevent cancer in people with HIV. We also study how these cancers develop and behave, using information from clinical trials to improve care and health outcomes.

Our **Scientific Working Groups** focus on developing new approaches for the management and prevention of cancers that disproportionately affect HIV-positive individuals, including:

- **Kaposi Sarcoma**
- **Hodgkin's and non-Hodgkin's Lymphoma**
- **Human Papillomavirus-related cancers** (e.g., anal and cervical cancers)
- **Cancers associated with tobacco and aging** (e.g., lung, head & neck, and other cancers)

Our **Committees** focus on supporting the Scientific Working Groups, as summarized below.

- **The Network Laboratory Resources Committee** oversees AMC's Central Laboratories that evaluate blood, tumor, and other biospecimens from AMC-coordinated studies.
- **The Career Enhancement Program** supports early career physicians and scientists pursuing careers focused on cancer occurring in people with HIV.
- **The Patient Outcomes, Survivorship, and Engagement Committee** promotes AMC's visibility through community awareness, provider education, and volunteer recruitment for AMC studies, and assures AMC studies include patient-reported outcomes that address survivorship concerns.
- **The International Resource Committee** oversees research at AMC's research portfolio at its sites in Africa and Latin America to assure that is relevant and feasible.

For more information about HIV-associated malignancies and AMC's research, please visit:

<http://www.AIDSCancer.org>